Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Rob Stepney participated in a radiotherapy clinical trial in Oxford in 2021. He talks about his experience on the trial and accessing a state-of-the-art machine that uses real-time imaging to improve tumour targeting.

Computer station used to process MRIdian data
Computer station used to analyse MRIdian results

In 2011, Rob Stepney was diagnosed with prostate cancer, and in 2020 the cancer had developed to a point where intervention was necessary. Prostate cancers are commonly treated with either surgery to remove the prostate, known as a prostatectomy, or radiotherapy, which is less invasive.

Fortunately, due to regular active surveillance, as soon as Rob’s tumour had progressed, his doctors were able to set up a treatment plan without delay. Rob was invited to participate in the PACE-C clinical trial, and was recruited to the study from its Oxford site.

Thanks to a new partnership between The University of Oxford, Oxford University Hospitals Trust, and leading UK cancer care provider, GenesisCare, Rob was able to access a new cutting-edge radiotherapy machine for this trial, known as the MRIdian. The MRIdian by ViewRay at GenesisCare in Oxford was the first of its kind in the UK, and is a revolutionary approach to radiotherapy – integrating MRI technology with radiotherapy to provide targeted, localised treatment whilst potentially minimizing side effects. 

Rob completed his treatment on the MRIdian at GenesisCare as part of the clinical trial in 2021, and his involvement will form part of wider studies to assess the feasibility and efficacy of using the technology to treat cancer, particularly tumours in hard-to-reach areas. Below, Rob recounts his experience of being part of an Oxford clinical trial and accessing this state-of-the-art technology.

Rob’s Clinical Trial Experience

 Rob StepneyRob Stepney

After ten years of monitoring a small prostate cancer through blood tests, biopsy and imaging, the time came – as I knew it would – when something definitive had to be done. The tumour had changed from a relatively non-threatening form to one that was more aggressive.

The choice was radiotherapy or surgery. Since the long-term results of the two approaches are similarly good, I chose the less invasive option of radiotherapy. At the time, we were being inundated by the second wave of the COVID-19 pandemic, so avoiding hospital admission also seemed sensible.

At that point, my oncologist at the Oxford University Hospitals NHS Foundation Trust, Dr Ami Sabharwal, asked whether I’d agree to be part of a clinical trial comparing the standard radiotherapy treatment plan against a new approach which involved fewer but more intense sessions.

Rob speaking with the GenesisCare teamRob speaking with the GenesisCare team Rob undergoing radiotherapy on the MRIdianRob undergoing radiotherapy on the MRIdian


In this new approach, the higher doses of radiation are delivered, whilst magnetic resonance imaging (MRI) allows doctors to see in real time the prostate and neighbouring healthy tissue, especially the bladder and rectum. This means that radiation delivery can be adapted so it only targets the tumour.  If the tumour moves out of target as when you breath, the treatment stops automatically until the tumour comes back into position, avoiding putting any other organs in the path of the radiation beam.

During my first treatment I realised how extraordinary it was to lie in the MRIdian machine and see my abdomen move on the scan as I breathed in and out.

Real-time imaging meant that I could lie in the scanner and see my abdomen move as I breathed

The hope for the MRIdian technology is that this new, ultra targeted approach - that precisely delivers the radiation beams to the tumour during each session - will better protect healthy tissues while allowing the maximum radiation dose to be delivered to the prostate tumour.

With any new treatment or technology research is needed to assess its benefits in terms of improved outcomes hence the need for clinical trials. When I enrolled in the study, I had a 50:50 chance of having the standard treatment. I was prepared to accept either.

As it happened, I was randomised to the new approach, which involved this machine, the MRIdian. It combines real-time scanning with a linear accelerator to deliver the radiation. As one of the research centres involved in the PACE-C trial, the University of Oxford obtained access to the machine through a partnership between the University of Oxford and GenesisCare, and to the staff expertly trained to operate it.

I was hugely impressed by the painstaking way the radiographers and oncologists marked up the images when they were planning the treatment. The cursor on the monitor (which I could see through a mirror in the scanner) moved from image to image to create contours and outline in areas to be targeted by the radiation, and distinguish them from other areas to be spared its effects.

It looked like a child’s colouring book where you can’t go over the lines – but the consequences of any inaccuracy would be more serious.

It looked like a child’s colouring book where you can’t go over the lines – but the consequences of any inaccuracy would be more serious 

After the course of treatment, which took five sessions over two weeks, I had the side effects I was told were likely: wanting to urinate frequently, and having difficulty doing so; and loose stools with small amounts of blood and mucus. However precisely the treatment is adapted, some healthy tissue experiences radiation and becomes inflamed. As I explained it to myself, it’s a bit like “a bad case of sunburn in a place where the sun don’t shine”. But the problems went away within two weeks.

As for the longer-term outcome, only time will tell, but I’m very hopeful. Radiotherapy has a good track record in eradicating small prostate tumours, and MR-guided, real-time targeting is the latest step in its evolution. I am very excited to have been part of the clinical trials in Oxford that are taking place to assess this technology and hopefully take it forward to standard clinical care, so that more people can benefit from it.

More information

Hear from Rob directly about his clinical trial experience and treatment on the MRIdian in a new video produced by Oxford Sparks.

Oxford Sparks is the University of Oxford’s platform for digital science engagement. They share the cutting-edge scientific research taking place at Oxford through their ‘Big Questions Podcast’, micro-documentaries and fun social media videos, which also explore ‘how science works’ and shine a spotlight on the researchers themselves. Catch all the latest Oxford Sparks content by following them on FacebookTwitter and Instagram, and subscribing to their YouTube channel.

Rob Stepney has spent 40 years a medical writer and journalist. Through working closely with medical specialists and now as a patient, he has a unique perspective on health research and new technologies. More about his work can be found in his recent book A foreign correspondent in medicine and on his website

For more information on the involvement of Oxford cancer researchers in MRIdian technology research see the full partnership announcement. The MRIdian machine at GenesisCare in Oxford was the first of its precise design in the UK, but several machines using the same principles are in use. The first such machine in the UK was installed in 2017 at the Royal Marsden Hospital Institute of Cancer Research, London.  Owing to the success of the first machine in Oxford, GenesisCare has now added a second machine at its central London centre at the Cromwell Hospital in London. 

The PACE-C trial forms part of the wider PACE trial sponsored by the Royal Marsden Hospital and coordinated by the Institute of Cancer Research (ICR). For more information on the PACE-C clinical trial see the CRUK webpage.

For more information on cancer clinical trials in Oxford and how to get involved see the Department of Oncology clinical trials webpage.

Similar stories

Glowing dye helps surgeons eradicate prostate cancer

A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study led by the University of Oxford.

New funding for development of world's first lung cancer vaccine

Oxford and UCL researchers seeking to create the world’s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to £1.7 million from Cancer Research UK and the CRIS Cancer Foundation.

Prof Anna Schuh launches first private specialised haematology clinic and laboratory in sub-Saharan Africa.

SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.

Professor Eileen Parkes appointed to lead Oxford’s Experimental Cancer Medicine Centre

Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre’s programmes in early drug development and biomarker research.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.